Edwards solidifies TAVR dominance in long-term trial readout

Edwards Solidifies TAVR Dominance in Long-Term Trial Readout

Edwards Lifesciences' transcatheter aortic valve replacement (TAVR) system has shown positive results in a long-term trial, as global demand for the technology increases.

The trial readouts demonstrated TAVR's comparable performance to surgical aortic valve replacement treatment. The company shared seven-year data from its PARTNER 3 trial, reaffirming the benefit of its SAPIEN 3 TAVR system in low-risk patients with aortic stenosis compared to surgery.

The data was presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.

The gold standard of business intelligence.

Author's summary: Edwards Lifesciences' TAVR system shows positive long-term results.

more

Medical Device Network Medical Device Network — 2025-10-28

More News